Overview

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Status:
Completed
Trial end date:
2019-02-27
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).
Phase:
Phase 2
Details
Lead Sponsor:
Allergan